XXXX is a putative target for the medical treatment of gonadotroph @entity652 of the pituitary.

@entity1 @entity5 @entity22260 @entity7931 @entity652 @entity7932
UNASSIGNED: Gonadotroph pituitary @entity652 (GPAs) often present as invasive macroadenomas not amenable to complete surgical resection. Radiotherapy is the only post-operative option for @entity1 with large invasive or recurrent lesions. No medical treatment is available for these @entity1 . The somatostatin analogs (SSAs) octreotide and lanreotide that preferentially target @entity7931 ( @entity7931 ) have little effect on GPAs. It is widely accepted that the expression of specific SSTR subtypes determines the response to SSAs. Given that previous studies on mRNA and protein expression of SSTRs in GPAs have generated conflicting results, we investigated the expression of @entity7931 , @entity22260 , and @entity7932 (the main targets of available SSAs) in a clinically and pathologically well-characterized cohort of 108 @entity1 with GPAs. A total of 118 samples were examined by immunohistochemistry using validated and specific MABs. Matched primary and recurrent tissues were available for ten @entity1 . The results obtained were validated in an independent cohort of 27 GPAs. We observed that @entity22260 was significantly more abundant than @entity7931 (P<0.0001) in GPAs, while full-length @entity7932 was only expressed in few @entity5 . Expression of @entity22260 was similar in primary and recurrent @entity652 , was high in potentially aggressive lesions, and did not change significantly in @entity652 that recurred after irradiation. In conclusion, low levels of expression of @entity7931 may account for the limited response of GPAs to octreotide and lanreotide. Given the potent anti-proliferative, pro-apoptotic, and anti-angiogenic activities of @entity22260 , targeting this receptor with a multireceptor ligand SSA such as pasireotide may be indicated for potentially aggressive GPAs.
